

PROGRAM OF THE 4th CEHC MEETING

9:00 - 9:10 Welcome address from the president of the CEHC and overview of the agenda
Robert Flisiak

9:10 - 9:15 Welcome address from the local member of the CEHC Board
Peter Jarcuska

9:15 – 10:55 New real world experience data of HCV treatment

- *J. Sperl (Czech Republic) DAA treatment of hemodialysed patients with HCV genotypes 1 or 3*
- *R. Flisiak (Poland) Long term follow-up after DAA treatment, an interim analysis of CE-Long study*
- *S. Frankova (Czech Republic) Impact of DAA treatment on the survival of liver transplant recipients*
- *B. Hunyady (Hungary) Real life experience of HCV therapy in Hungary*
- *P. Jarcuska (Slovakia) Topic 1 - reserved*
- *I. Grugevic (Croatia) Impact of HCV cure by DAAs on portal hypertension and HCC risk*

10:55 – 11:10 Coffee break

11:10 – 12:10 Screening for HCV and other topics

- *M. Makara (Hungary) Screening in practice: target populations and methods*
- *K. Tomasiewicz (Poland) Evaluation of HCV screening intervention in Poland*
- *P. Jarcuska, P. Kristian (Slovakia) Topic 2 - reserved*

12:10 – 12:30 Discussion on CEHC possible activities – Governing Board and all participants

12:30 – 12:35 Closing remarks
Robert Flisiak



June 16th 2017